Showing results (101-110 of 139) with videos related to

Sort By:
Pageof 14
Cancer Research Communications|April 19, 2026
Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung CancerMichael Conroy, Jaime Wehr, Vivian V Altiery De Jesus, et al.
Molecular Cancer Therapeutics|March 16, 2026
TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancerDipanwita Dutta Chowdhury, Eddie L Imada, Nick Connis, et al.
Current Oncology (Toronto, Ont.)|June 23, 2022
An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive AnalysisKai-Li Liang, Sean Tackett, Samantha Myers, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2021
Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapyCole Friedes, Turja Chakrabarti, Sarah Olson, et al.
Science (New York, N.Y.)|September 4, 2009
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastomaRobert L Yauch, Gerrit J P Dijkgraaf, Bruno Alicke, et al.
The New England Journal of Medicine|September 4, 2009
Inhibition of the hedgehog pathway in advanced basal-cell carcinomaDaniel D Von Hoff, Patricia M LoRusso, Charles M Rudin, et al.
ESMO Open|December 10, 2023
Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasisK Liang, J L Feliciano, K A Marrone, et al.
The Oncologist|August 16, 2022
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer ImmunotherapyMelinda L Hsu, Joseph C Murray, Kevin J Psoter, et al.
Journal of Neuro-Oncology|July 16, 2025
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastasesTia Cheunkarndee, Zsombor Ritter, Max Saint-Germain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumorsLeena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.
Pageof 14